Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme
Authors' conclusion
In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS-2, SURPASS-3 and SURPASS-4, suggesting that both weight-independent and weight-dependent mechanisms are responsible for the tirzepatide-induced improvement in glycaemic control.
Study context
- Population
- People with T2D treated with tirzepatide in SURPASS-1 to −5
- Comparison
- Tirzepatide 5, 10 or 15 mg: relationship between HbA1c and body weight change
- Primary endpoint
- Relationship between HbA1c and body weight reductions
- Follow-up
- 40 weeks (SURPASS-1, −2, −5); 52 weeks (SURPASS-3, −4)
Methodological detailsanalysed by trial
- Analysed by trial
Primary result
As reported in the abstract
HbA1c reduction from baseline (range across trials)
Tirzepatide 5 mg
96%-99%
Tirzepatide 10 mg
98%-99%
Tirzepatide 15 mg
94%-99%
- Significant associations between HbA1c and body weight changes in SURPASS-2, −3, −4 (all doses) and −5 (5 mg only); correlation coefficients across studies
- 0.1438 to 0.3130; P ≤ .038
Further findings
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg |
|---|---|---|---|
| Weight loss associated with HbA1c reduction (range across trials) | 87%-94% | 88%-95% | 88%-97% |
Original publication
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme. Diabetes Obes Metab. Published 29 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →